Mohamed Yassine
About Mohamed Yassine
Mohamed Yassine serves as the Senior Vice President of Global Medical Affairs at Aimmune Therapeutics, having previously held significant roles at Amgen and UCB in various medical affairs capacities.
Current Role at Aimmune Therapeutics
Mohamed Yassine serves as the Senior Vice President of Global Medical Affairs at Aimmune Therapeutics. He has held this position since 2020, contributing to the company's strategic direction in medical affairs. His role involves overseeing medical strategies and ensuring alignment with the company's objectives in the biopharmaceutical sector. Aimmune Therapeutics focuses on developing treatments for food allergies, and Yassine's expertise is instrumental in guiding medical initiatives.
Previous Experience at Amgen
Mohamed Yassine has extensive experience at Amgen, where he held multiple roles. He worked as an Executive Director and Therapeutic Area Lead for Inflammation from 2010 to 2014. He also served as a Medical Director in Oncology within Global Clinical Development from 2006 to 2008. Additionally, he was an Associate Director in Oncology from 2004 to 2006 and held the position of Director of Scientific Affairs from 2009 to 2010. His tenure at Amgen spanned over a decade, during which he contributed to various therapeutic areas.
Experience at UCB
At UCB, Mohamed Yassine held significant roles in the medical affairs domain. He was the Head of US Immunology Medical Affairs from 2015 to 2018, where he led initiatives in immunology. Following this, he served as the Head of US Medical Affairs from 2018 to 2019. His work at UCB focused on advancing medical strategies and enhancing the company's presence in the immunology field.
Educational Background and Expertise
While specific details about Mohamed Yassine's educational background are not provided, his extensive career in medical affairs and leadership roles in the pharmaceutical industry indicate a strong foundation in medical science and clinical development. His expertise spans various therapeutic areas, including oncology, inflammation, and immunology, reflecting a comprehensive understanding of the biopharmaceutical landscape.